Latest news

New film from Eiffage about Ironhand®

Bioservo publishes prospectus and invites to investor presentations (regulatory information)

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

24 Jun, 2019

Bioservo Technologies announces the start of the clinical study for Carbonhand® within the framework of the Horizon 2020 iHand project

Bioservo Technologies AB (publ) (Nasdaq First North: BIOS) has engaged Roessingh Research and Development in the Netherlands to coordinate a clinical trial studying the rehabilitation effects of Carbonhand on patients with an impaired hand function, which is part of the iHand project.

Supporting this, a total of seven Dutch rehabilitation centres are collaborating: UMCG Centre for Rehabilitation (Groningen), Isala (Zwolle), Reade Rehabilitation / Rheumatology (Amsterdam), Rijndam Rehabilitation (Rotterdam), De Hoogstraat (Utrecht), Sint Maartenskliniek (Nijmegen) and Roessingh, Centre for Rehabilitation (Enschede). In addition, Clinical Trial Service B.V., a contract research organisation, is involved in the execution and monitoring of the study.

The primary objective of the study is to investigate the effect of Bioservo’s healthcare glove, Carbonhand, on the patients own maximum grip force without support. This study is conducted with patients having an impaired hand function. Their grip strength is measured before and after they have used the glove continuously for six weeks in their home environment. In addition, the secondary objectives of the study are the improvement of the arm/hand function, the degree of use of the glove and the quality of life of the patients. By using Caronhand, patients can stimulate the use of their affected hand and thus increase their mobility as well as their independence. A total of 63 patients are participating in the study with the first patient starting already 25 June.

A broad range of different patient groups, such as orthopedic patients, rheumatic patients, patients with incomplete spinal cord injury, traumatic brain injury and patients with a stroke often experience problems in carrying out activities in daily life as a result of an impaired hand function. They need personal assistance and/or tools to perform all kinds of daily activities. Carbonhand supports the gripping movement by strengthening the grip. Therefore, the wearer utilizes his/her affected hand more in daily life, which may lead to more independence and an improved hand function after a period of use.

All participants were asked to use Carbonhand for a period of six weeks in their home environment during daily tasks. Participants are encouraged to use the glove during all activities where additional support is needed.

About Carbonhand®
Carbonhand is a grip enhancing robotic glove that facilitates a normal movement pattern. It adds extra strength when needed the most and it reinforces the hand’s functions. Carbonhand improves strength and endurance in the hand for people with impaired hand function. Carbonhand’s development and improvement are partly covered by the iHand project. The iHand project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 801945.

About Bioservo Technologies
Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimise the body’s endurance and performance, or for people with reduced muscle strength.

After many years of research and development, Bioservo Technologies is now focused on a commercialisation of the company’s products and patented technologies. The gloves are well-suited to medical rehabilitation, and to preventive use in a variety of industrial applications. The company has signed strategic cooperation agreements with several multinational companies within e.g. the automotive, aviation as well as the construction and infrastructure industry.

Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public limited company with its headquarters and operations based in Kista, north of Stockholm. FNCA Sweden AB, +46(0)8-528 00399, info@fnca.se,is the company’s Certified Adviser on Nasdaq First North. To learn more, please visit www.bioservo.com.

Contact:

Petter Bäckgren
CEO
Phone: +46 (0)8 21 17 10
petter.backgren@bioservo.com

Peter Löwendahl
Quality and Regulatory Affairs Director
Phone: +46 (0)8 21 17 10                                                                                   
peter.lowendahl@bioservo.com

About Roessingh Research and Development

Roessingh Research and Development (RRD) is a large scientific research institute focused on rehabilitation technology and eHealth. RRD works closely with Roessingh, Centre for Rehabilitation and the University of Twente in the field of rehabilitation technology and eHealth, but also with (international) partners. More information: www.rrd.nl

Contact:
Anke Kottink
Researcher RRD,
Phone: + 31 088 087 5733